Biotrin assay to monitor cervical cancer exposure rates

Article Abstract:

Dublin-based Biotrin's immunoassays can be used to guarantee the integrity of the cervical cancer immunization programs by using either Gardasil or Cervarix, which are recombinant vaccines against multiple subtypes of human papilloma virus (HPV). Biotrin has licensed the technology from the U.S. National Cancer Institute (NCI) and it aims to use the assays to track the effectiveness of immunization programs.

Diagnosis, Prevention, Cervical cancer, Immunoassay, Cancer vaccines

---

Fast track to MS drug

Article Abstract:

The launch of the humanized monoclonal antibody Antegren developed by Biogen Idec of Cambridge, Massachusetts, and Elan of Dublin as a treatment for multiple sclerosis is poised to shake the market now dominated by a handful of products. The issue, whether the new multiple sclerosis drug Antegran would be the next blockbluster drug, as predicted by some analysts is discussed.

Manufacturing processes, Care and treatment, Biological products industry, Production processes, Multiple sclerosis, Monoclonal antibodies, Biogen Idec Inc., Massachusetts Behavioral Health Partnership

---

Production technologies change flu vaccine landscape

Article Abstract:

The sanction of the first seasonal influenza vaccine based on mammalian cell culture in the European Union, represents the start of technological transition from the 50-year old, egg-based manufacturing procedure in the industry.

Production management, Influenza vaccines, Cell culture

Similar abstracts:

• Abstracts: Wolfowitz says aerial tanker deal must be rebid . Wolfowitz seeks technology for bio-defense systems. Wolfowitz warns war on terrorism may last longer than Cold War
• Abstracts: Big pharma wants you. The rise of venture capital and biotechnology in the US and Europe. Term sheet trends in the venture capital market
• Abstracts: US court case to define EST patentability. EPO neem patent revocation revives biopiracy debate. IP litigation in China could drive innovation
• Abstracts: Chimeras in the crosshairs7. Boutiques reborn in 2003
• Abstracts: Late to dinner table carb makers join party. Nike, Adidas PR challenged by Starbury 'cheap' sneaker line. Ford is latest reversal in culture war clash

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.